Beta counters

RN 22

MYCL-9E10

Application PR-619 has been used: as a component of lysis buffer and also as a deubiquitinase inhibitor to treat proteins derived from SILAC-labeled Jurkat cells as a pan-deubiquitinase inhibitor to study its effect on adenoassociated virus

Application PR-619 has been used: as a component of lysis buffer and also as a deubiquitinase inhibitor to treat proteins derived from SILAC-labeled Jurkat cells as a pan-deubiquitinase inhibitor to study its effect on adenoassociated virus

Biochem/physiol Actions LMT-28 is a derivative of oxazolidinone. It has the ability to repress the activation of signal transducer and activator of transcription 3 (STAT3) stimulated by interleukin 6 (IL-6).

Biochem/physiol Actions LMT-28 is a derivative of oxazolidinone. It has the ability to repress the activation of signal transducer and activator of transcription 3 (STAT3) stimulated by interleukin 6 (IL-6).

Biochem/physiol Actions PRT-060318 (PRT318: P142-76) is a highly potent and selective Syk inhibitor (IC50 = 4 nM: much reduced potency against 138 other kinases) that blocks BCR-dependent signaling in chronic lymphocytic leukemia (CCL) cultures

Biochem/physiol Actions PRT-060318 (PRT318: P142-76) is a highly potent and selective Syk inhibitor (IC50 = 4 nM: much reduced potency against 138 other kinases) that blocks BCR-dependent signaling in chronic lymphocytic leukemia (CCL) cultures

Biochem/physiol Actions RCM-1 is a forkhead box M1 (FOXM1) inhibitor that blocks FOXM1 nuclear localization (IC 50 = 720 nM using GFP-FOXM1-expressing U2OS cells) and causes FOXM1 degradation via ubiquitination induction (2.9- and 4.

Biochem/physiol Actions RCM-1 is a forkhead box M1 (FOXM1) inhibitor that blocks FOXM1 nuclear localization (IC 50 = 720 nM using GFP-FOXM1-expressing U2OS cells) and causes FOXM1 degradation via ubiquitination induction (2.9- and 4.

Biochem/physiol Actions SAR-20347 is an orally active, ATP-competitive, TYK2- and JAK1-selective tyrosine kinase inhibitor (IC 50 = 13 nM/TYK2 &amp: 59 nM/JAK1 vs. 0.

Biochem/physiol Actions SAR-20347 is an orally active, ATP-competitive, TYK2- and JAK1-selective tyrosine kinase inhibitor (IC 50 = 13 nM/TYK2 &amp: 59 nM/JAK1 vs. 0.